Search Weight Loss Topics:

Page 13«..10..12131415..2030..»

Home » Page 13

Im Dani Blum, a reporter on the Well desk, filling in for Jancee Dunn today. Part of my job is making sense of the endless array of wellness trends that take over the internet. Some days, that means chasing down the answers to age-old questions; other days, Im investigating new products.

As we slip into summer, and the second half of the year, lets look back at the health trends that have defined 2024 so far.

The water wars are here, and they are vicious thanks, #Watertok. Theres a fierce online community extolling the benefits of hydration and igniting debates over just how much water people need to drink each day and whether plain old H2O is enough.

So how and how often should you refill your water bottle? Theres no one right answer for everyone, and most people can stay hydrated by just reaching for water when they feel thirsty. But watch out for the black gunk that can collect at the bottom of your water bottle if youre wondering if thats mold, the answer (sorry) is yes.

Products that claim to heal and hack your gut have become a staple of wellness culture. In 2024, the gut has gotten a glow up: Pastel cans of prebiotic sodas have popped up on store shelves; the microbiome has gone mainstream; and people are adding apple cider vinegar into their drinks, hoping to cure acid reflux.

Amid all the hype, gastroenterologists want to clarify a few things: namely, that there are ways to help the gut, but few are trendy. Eat plenty of fiber, limit processed foods and lower stress to keep your belly happy and healthy.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit andlog intoyour Times account, orsubscribefor all of The Times.

Thank you for your patience while we verify access.

Already a subscriber?Log in.

Want all of The Times?Subscribe.

Go here to read the rest:
Hurkle-Durkling, Prebiotic Sodas and Other Health Trends Defining 2024 - The New York Times

Read More..

In addition to health coaching, Ive been a personal trainer for over 20 years, and one accessible way Ive seen clients get those bursts of physical activity is set aside 30 minutes after dinner for a walk, bike ride or quick workout using a variety of fitness apps.

If possible, think of it as leisure time or a way to clear your head. Bring a family member or meet up with a friend, or listen to a favorite podcast, music or audiobook.

Eighteen of those 30 minutes can be low intensity, but if you include three to four moderate- to high-intensity intervals lasting at least three minutes each, this research indicates your efforts will go a long way toward taking excellent care of your heart health.

Imagine the nutrients you ate at dinner fueling your body as you goprotein, healthy fat and carbohydrates. Put them to use to strengthen your body before winding down for the night.

Morning or midday exercise is wonderful for your health as well. Find what works for you, and if you want to step your fitness up a notch, consider adding a few quick bouts of exercise in the afternoon or evening. The most important questions to guide your decisions are:

What does your schedule allow? And when are you most likely to lace up your sneakers and get moving?

Your answers are the best bet to take care of both your heart and your spirit.

Hey, Health Coach is for informational purposes only and should not substitute for professional psychological or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions about your personal situation, health or medical condition.

By submitting your letter to heyhealthcoach@forbesadvisor.com, you agree to let Forbes Health use it in part or in whole, and we may edit the letter for length and clarity. All submissions remain anonymous.

Transform Your Fitness With Science-Based Training

Download the free Caliber app and discover how the average member achieves at least a 20% improvement to their body composition within 3 months.

Go here to read the rest:
What Time Of Day Is Best To Exercise For Heart Health? - Forbes

Read More..

But an important, new, long-term study of people who used and then quit one of the weight-loss drugs suggests there may be a simple, accessible way to stave off unhealthy weight regain after stopping the drugs: exercise.

In the study, people who exercised while using a weight-loss drug kept off far more of their weight after quitting the medication than people who didnt work out, and they maintained more muscle.

Signe Srensen Torekov, a professor of biomedical sciences at the University of Copenhagen in Denmark and senior author of the new study, said the results strongly indicate that people using the drugs may be able to preserve a healthy weight, even after they quit the medication. But they do need to do exercise.

Weight loss, with a catch

Most obesity experts agree that the holy grail of healthy, long-term weight loss is maintenance. Shedding pounds is possible for many people, in the short term. Keeping it off can seem almost impossible.

The new class of GLP-1 diabetes or weight-loss drugs, with brand names such as Ozempic, Wegovy, Zepbound and Mounjaro, seem to be intensifying that dynamic. GLP-1 is short for glucagon-like peptide 1 agonist; these drugs mimic the effects of the substance GLP-1.

Most people lose substantial weight rapidly on these drugs. But if they stop, the pounds typically return almost as quickly.

But is this rebound inevitable?

Torekov and her colleagues devised a multiyear, multipronged effort to find out.

It began with 195 Danish adults with obesity but no other major illnesses. They were put on an extremely low-calorie diet, under the supervision of the scientists, to rapidly lose about 30 pounds. Since this was to be a weight-maintenance study, the scientists wanted them to drop pounds fast, and then move to the maintenance phase.

For that phase, the researchers assigned some of the volunteers to start taking Saxenda, known generically as liraglutide, an early GLP-1 medication, to see if the drug would help them maintain and even augment their dieting weight loss. Saxenda is made by Novo Nordisk, the company that also makes two similar drugs the diabetes drug Ozempic and the weight-loss drug Wegovy.

(The study was funded in part by the Novo Nordisk Foundation, a charitable organization affiliated with Saxendas maker. The pharmaceutical company itself had no oversight of the study or its results, a company spokesperson said.)

A separate group of volunteers started the same drug, but also a supervised exercise program, with twice-weekly, half-hour group spinning classes and 15 minutes of high-intensity, full-body resistance training, along with two at-home jogs or similar workouts. The exercise was mostly vigorous, meaning strenuous enough that people could barely talk while they were working out.

A control group didnt exercise and received a placebo, instead of liraglutide.

After a year, almost everyone who took the drug had maintained the lower weight or lost more weight.

Those combining the drug and exercise had lost the most, though. Theyd dropped about six pounds more than those on the drug alone, and more of those pounds consisted of fat, instead of muscle.

What happened when they stopped the drug

The researchers published those results in 2021 in the New England Journal of Medicine. Then they began the most revelatory aspect of their study. They ended the medications and exercise sessions for everyone, leaving people to maintain or regain their weight-loss completely on their own.

After a year passed, the researchers invited all the volunteers back to the lab. One hundred and nine returned and researchers checked their body weight, body composition and current exercise habits.

For some, the year had been discouraging. Those whod earlier taken the weight-loss drug without exercise regained about 70% or more of all the weight theyd lost since the start of the study. Most of these regained pounds were in the form of fat, not muscle, so they wound up with relatively higher percentages of body fat than before starting the drug.

But those whod exercised while taking the drug had maintained considerably more of their weight-loss during this phase. Many remained at least 10% lighter than at the studys start, and at least some of the weight theyd regained was muscle, leaving them with a healthier body composition than the other groups.

Exercising just two hours a week

Its easy to understand why the exercisers added fewer pounds after stopping the drug, Torekov said. They were still exercising, even without supervision or nudging from the scientists. According to questionnaires and activity trackers, they generally continued to work out for several hours a week, voluntarily.

These findings suggest about two hours a week of vigorous exercise, may be a good goal for staving off weight regain after ceasing a weight-loss drug, she continued. Mixing aerobic and resistance exercise is probably best.

Meanwhile, those whod taken the drug without exercise were almost completely sedentary now, averaging fewer than 30 minutes of exercise a week.

More of the ones who had not exercised while medicated had complained of fatigue during treatment and afterward, Torekov said, which may have contributed to their inactivity now.

Overall, the results make a strong case for the importance of adding exercise to a regimen that includes a GLP-1 medication, said Daniel Drucker, a diabetes expert and senior investigator at the Lunenfeld-Tanenbaum Research Institute in Toronto, whose research helped pave the way for the GLP-1 drugs. He wasnt involved with the new study.

The results are very encouraging, agreed Robert Kushner, an endocrinologist and professor at Northwestern University Feinberg School of Medicine, who specializes in weight loss. But further studies will need to be performed to see if a less intense exercise routine has similar effects on weight maintenance when people stop a GLP-1 drug.

See the original post here:
Why the long-term success of weight-loss drugs may depend on exercise - The Atlanta Journal Constitution

Read More..

Fast food is not a "healthy" option to regularly turn to when dieting or trying to lose weight. However, certain menu options at popular chains like Popeyesare better than others in terms of calorie counts and nutritional profiles. After all, any weight-loss regimen needs to be sustainable for long-term results, and completely depriving yourself of the foods you love most can seriously backfire. So, when it's time to treat yourself, we have the best Popeyes order for weight loss that's dietitian-approved. It will satisfy the cravings without derailing your efforts.

Nutrition (Per meal): Calories: 400 Fat: 25 g (Saturated Fat: 12 g) Sodium: 780 mg Carbs: 37 g (Fiber: 3 g, Sugar: 2 g) Protein: 8 g

Popeyes' Bacon Biscuit isthe best breakfast option for weight loss, according to Jessie Anderson, MS, RD, CSSD, LD, ACSM EP-C, a board-certified specialist in sports dietetics from Top Nutrition Coaching.

"Carbohydrates [are] the body's primary energy source; the Bacon Biscuit contains a moderate serving of carbohydrate along with 3g of fiber to promote stamina, focus, and energy to start the day strong," explains Anderson. "Moderate levels of protein help aid satiety and fullness between meals."

The 10 Best & Worst Menu Items at Popeyes, According to a Nutritionist

Keep in mind that the Bacon Biscuit has 12g of saturated fats. According to the American Heart Association (AHA), consuming saturated fat in excess can increase the amount of LDL cholesterol in your blood. This, in turn, could heighten your chances of suffering from stroke and heart disease. It's recommended by the AHA that you limit saturated fat to just 5% to 6% of your daily calorie count.

The #1 Healthiest Order at 9 Major Fast-Food Chicken Chains

Nutrition (Per meal): Calories: 400 Fat: 23 g (Saturated Fat: 8 g) Sodium: 1,220 mg Carbs: 34 g (Fiber: 7 g, Sugar: 0 g) Protein: 21 g

Ordering at Popeyes with weight loss in mind means exploring the kids' menu. The Tender Classic is 150 calories and provides a whopping 13 grams of protein. The side of Red Beans and Rice is 250 calories in a regular-sized portion and offers eight grams of protein and six grams of fiber, both of which are crucial for weight loss and management to promote satiety.

"Kids meals are a great way to moderate portions while still enjoying your favorite foods from fast-casual locations," Anderson tells us. "Popeyes Kids Tender Classic Meal is low in saturated fats and contains 0g of trans-fats and added sugars [adding] a regular side of red beans and rice makes this a complete mealoffering additional protein and a fiber-boost to promote sustained energy, focus, immune support, and heart health."

I Tried Popeyes for the First Time Ever and This Item Really Is a Showstopper

Sign up for our newsletter! 6254a4d1642c605c54bf1cab17d50f1e

Alexa Mellardo

Here is the original post:
The Best Popeyes Order for Weight Loss - Eat This, Not That

Read More..

Dr. Brian Nadler and two of his family members have initiated a lawsuit against Hawkesbury and District General Hospital (HGH).

According to a CBC report on Thursday, July 4, Nadler is suing HGH for $20 million in damages for alleged defamation, abuse of process, and conspiracy, accusing HGH staff of making an abrupt, erroneous and defamatory decision to involve police. Nadler, who was working at HGH at the time, was charged with First-Degree murder in March 2021 in connection with the death of 89-year-old HGH patient Albert Poidinger. Police later laid three additional charges of First-Degree murderconnected to the deaths of 80-year-old Claire Brire, 79-year-old Lorraine Lalande and 93-year-old Judith Lungulescu.

On July 2, Nadler was acquitted of the murder charges, and of four charges of Criminal Negligence Causing Death due to inadmissible evidence during the pre-trial proceedings.

The lawsuit, filed in April 2023, also names Nadlers mother Susan Epstein and his sister Erica Nadler as plaintiffs.

HGH has declined to comment about the lawsuit to The Review.

View original post here:
Nadler and family members suing HGH - The Review Newspaper

Read More..

Mumbai: Actress Kajal Aggarwal and celebrity chef Vicky Ratnani launched their brand licencing programmes at HGH India. HGH India is a bi-annual trade show for home textiles, home dcor, home furniture, houseware and gifts.

Partnering with Swag, a lrand licensing company Aggarwal aims to bring her home design ideas to life under her brand Kateeka. Her Brand Licensing Programme looks to integrate traditional artistry with modern design sensibilities. She aims to develop premium home lifestyle products that resonate with both heritage enthusiasts and modern homeowners.

She said, At this stage in my life, focusing on Home Lifestyle categories comes naturally. I am deeply passionate about the vibe and design aesthetics that shape our homes. I am looking forward to bringing my home design ideas to fruition through my brand and am excited to meet and engage with industry leaders at HGH India to explore potential collaborations.

HGH India also enabled the launch of Ratnanis journey into kitchenware through a strategic collaboration with Swag. This initiative marks his foray into the kitchenware sector. He said, I wanted to translate my global experiences into creating products that resonate with Indian households while offering a chic, international aesthetic. His Brand Licensing Programme aims to redefine kitchenware, leveraging his understanding of culinary essentials to inspire cooking aficionados nationwide.

Read the rest here:
Actress Kajal Aggarwal, chef Vicky Ratnani launch their brand licencing programmes at HGH India 2024 - MediaNews4U

Read More..

Partnering with Swag, a brand licensing company for creating and establishing some of Indias most prominent celebrity-led brands, Kajal Aggarwal aims to bring her visionary home design ideas to life under her brand Kateeka.

Read More

Her Brand Licensing Program promises to integrate traditional artistry with modern design sensibilities. She aims to develop premium home lifestyle products that resonate with both heritage enthusiasts and modern homeowners.

Kajal Aggarwalsaid, At this stage in my life, focusing on Home Lifestyle categories comes naturally. I am deeply passionate about the vibe and design aesthetics that shape our homes. I am looking forward to bringing my home design ideas to fruition through my brand and am excited to meet and engage with industry leaders at HGH India to explore potential collaborations.

HGH India also enabled the launch of Chef Vickys transformative journey into kitchenware through a collaboration with Swag. This initiative marks Chef Vickys ambitious foray into the kitchenware sector.

Chef Vicky Ratnani, said, I wanted to translate my global experiences into creating products that resonate with Indian households while offering a chic, international aesthetic.

His Brand Licensing Program is poised to redefine kitchenware, leveraging his deep understanding of culinary essentials to inspire cooking aficionados nationwide.

Could not have been a better platform to launch its brand licensing programs as HGH India has been working with the home improvement sector for over a decade now. It is the only trade show that is designed to connect Indian and global home product brands and manufacturers with the Indian domestic market.

The show integrates home textiles, home decor, home furniture, and houseware under one roof to provide sourcing solutions to retailers, distributors, importers, architects, interior designers, and institutional buyers, keeping upcoming design trends in focus.

Read more here:
Kajal Aggarwal and Vicky Ratnani unveil Brand Licensing Program at HGH India 2024 - Mediabrief

Read More..

GLP-1 medications such as Ozempic and Wegovy may help lower the risk of certain cancers, a new study suggests.People who are overweight or obese have a higher risk of getting 13 types of cancer, and the risk increases the longer a person is overweight and the more excess weight they gain. About 40% of new cancer diagnoses are associated with excess weight, according to the U.S. Centers for Disease Control and Prevention. In 2021, there were about 170 new diagnoses for every 100,000 people, CDC data shows.But a study published Friday in the journal JAMA Network Open found that people with type 2 diabetes who were being treated with a class of GLP-1 drugs were significantly less likely to be diagnosed with 10 of the 13 obesity-associated cancers than those who were taking insulin.The risk was cut by more than half for gallbladder cancer, meningioma, pancreatic cancer and hepatocellular carcinoma, a kind of liver cancer. It was also significantly reduced for ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer, endometrial cancer and kidney cancer.Excess weight can cause changes in the body such as long-lasting inflammation and higher than normal levels of insulin, insulin-like growth factor and sex hormones that can cause cancer, according to the CDC. And GLP-1 medications interact with systems related to insulin production.The new findings that link GLP-1 treatment to reduced risk of some cancers "compare favorably" with similar effects linked to intensive lifestyle intervention and metabolic-bariatric surgery that have been found in other trials, the study authors wrote.However, the research found that GLP-1 treatment was not associated with a reduced risk of postmenopausal breast cancer, which CDC data shows is the most common type of cancer associated with obesity.Risk was also not reduced for stomach cancer or thyroid cancer. In fact, other research has found that GLP-1s may interact with the body's insulin production in ways that negatively affect the thyroid, and the study authors note that patients should be aware of potential thyroid-related risks that are included on the medication's packaging.The new study also found that the risk of cancer diagnosis for people with type 2 diabetes was not different among those who were treated with GLP-1s compared with those where were being treated with metformin. In fact, the risk of diagnosis with kidney cancer was higher among those using GLP-1s than those on metformin.For this study, researchers from the Case Western Reserve University School of Medicine and the MetroHealth System analyzed more than a decade of medical records for nearly 1.7 million people with type 2 diabetes.More information is needed about how reduced cancer risk may relate to the scale of weight loss, but the findings provide "preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies," the study authors wrote.

GLP-1 medications such as Ozempic and Wegovy may help lower the risk of certain cancers, a new study suggests.

People who are overweight or obese have a higher risk of getting 13 types of cancer, and the risk increases the longer a person is overweight and the more excess weight they gain. About 40% of new cancer diagnoses are associated with excess weight, according to the U.S. Centers for Disease Control and Prevention. In 2021, there were about 170 new diagnoses for every 100,000 people, CDC data shows.

But a study published Friday in the journal JAMA Network Open found that people with type 2 diabetes who were being treated with a class of GLP-1 drugs were significantly less likely to be diagnosed with 10 of the 13 obesity-associated cancers than those who were taking insulin.

The risk was cut by more than half for gallbladder cancer, meningioma, pancreatic cancer and hepatocellular carcinoma, a kind of liver cancer. It was also significantly reduced for ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer, endometrial cancer and kidney cancer.

Excess weight can cause changes in the body such as long-lasting inflammation and higher than normal levels of insulin, insulin-like growth factor and sex hormones that can cause cancer, according to the CDC. And GLP-1 medications interact with systems related to insulin production.

The new findings that link GLP-1 treatment to reduced risk of some cancers "compare favorably" with similar effects linked to intensive lifestyle intervention and metabolic-bariatric surgery that have been found in other trials, the study authors wrote.

However, the research found that GLP-1 treatment was not associated with a reduced risk of postmenopausal breast cancer, which CDC data shows is the most common type of cancer associated with obesity.

Risk was also not reduced for stomach cancer or thyroid cancer. In fact, other research has found that GLP-1s may interact with the body's insulin production in ways that negatively affect the thyroid, and the study authors note that patients should be aware of potential thyroid-related risks that are included on the medication's packaging.

The new study also found that the risk of cancer diagnosis for people with type 2 diabetes was not different among those who were treated with GLP-1s compared with those where were being treated with metformin. In fact, the risk of diagnosis with kidney cancer was higher among those using GLP-1s than those on metformin.

For this study, researchers from the Case Western Reserve University School of Medicine and the MetroHealth System analyzed more than a decade of medical records for nearly 1.7 million people with type 2 diabetes.

More information is needed about how reduced cancer risk may relate to the scale of weight loss, but the findings provide "preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies," the study authors wrote.

Continued here:
Popular weight-loss and diabetes medications linked to lower risk of some cancers, study finds - WVTM13 Birmingham

Read More..

First Opinion is STATs platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them. You can submit a Letter to the Editor here, or find the submission form at the end of any First Opinion essay.

Psychiatrists arent fulfilling the social contract that subsidized their training, by Richard G. Frank

While I appreciate the sentiment, this article is incomplete at best, and oversimplifies a complex calculus. Physician training is, of course, subsidized by the Medicare and Medicaid systems; most residency positions are, and not just in psychiatry. However, are we leveling this at the other specialty physicians who are not accepting Medicare and Medicaid patients? Additionally, the reimbursement in psychiatry is not level it is much more limited and not equitable compared to other specialties, particularly surgical/procedural specialties. This makes it harder for psychiatrists to pay the bills when accepting a lower rate of reimbursement than other physicians even though the student loan bills are still there.

I agree that the social-ethical contract is compelling for psychiatrists to accept all of these patients. However, substantial deficits and inequities in the health care systems shouldnt be placed on psychiatrists to take sole responsibility for.

At the same time that we should encourage psychiatrists to accept a wider range of patients, we should also be calling out the inequities in the payment system, mental health parity laws that are largely unenforced (and thus meaningless) rendering an unfair system for patients seeking care and psychiatrists seeking reimbursement for care provided.

As with most issues in health care, its complicated.

Michael J. Peterson, Department of Psychiatry, University of Wisconsin School of Medicine and Public Health

***

Thanks for reminding me of my social contract. I need a favor: review the back door meetings of the Medicare Act of 1965 that resulted in non-procedure based care being reimbursed (and considered less important) than procedure-based care. Give us the demographics of these decision-makers (Im assuming all cisgendered heterosexual white guys). Share with us how extrapolating this built-in financial discrimination has resulted in psychiatrists not taking insurance. In other words: do real research before throwing stones in glass houses.

Brian Dixon

***

This article ignores the very obvious elephant in the room. It implies that the money paid by Medicaid/Medicare to support psychiatry residents actually translates into some kind of fair compensation for their work during residency. Residents work 60-80 hours per week during residency. In return we are paid somewhere between $40,000 and $60,000 a year at the beginning of our training, which grows to somewhere between $50,000 to $70,000 by the end. In short, we are paid about $19 per hour for some of the most highly skilled work in the country. I think that fulfills our social contract quite nicely.

Karen Abdool

***

While Richard G. Franks recent First Opinion piece calls attention to the problem of lack of access to mental health services, it inappropriately lays blame for that problem at the feet of psychiatrists. To the contrary, psychiatrists are working within complex systems and advocating fiercely to ensure the widespread provision of quality care.

For those who are choosing not to take insurance, the simple truth is that the finances dont add up. Psychiatrists leave training with medical school debt, are paid less per hour than primary care physicians and even physician assistants, and need to spend time or dollars on staff to help deal with administrative complexities like prior authorization. As Frank points out, insurers, in an effort to cut their own costs, have limited networks, established inadequate fee schedules, and created administrative barriers to mental health services. This leaves psychiatrists in a bind when trying to serve patients without going into the red: and still, only 7.7% of psychiatrists have opted out of Medicare. Many of our members and colleagues clearly want to take insurance, including Medicare and Medicaid, but in this reality, sometimes we cant.

We want this situation to change and we are working hard on solutions. Advocacy for mental health parity is imperative. Parity wont be achieved without adequate reimbursement, and we are working with the Center for Medicare and Medicaid services and public and private payors to achieve it.

Meanwhile, demand for psychiatric services has grown exponentially, and we cannot increase the number of psychiatrists fast enough to meet this need. While more graduate medical examination slots have been created in recent years and the field is more popular than ever, our physician members advocate to ensure we maintain a strong pipeline to bring in more qualified psychiatrists.

Psychiatrists are also on the forefront of advocating for transformative care delivery models and modalities that will allow for better access, including telepsychiatry, and team-based care to expand access for all individuals. Whether through integrated care options like Collaborative Care or working on teams in other models, were innovating to reach patients like never before.

The failure is not one of individual choices, but rather a systemic failure to fund and support access to psychiatric care. As it stands today, the field is forced to leverage its scarce resources to serve the needs of a country facing a mental health crisis.

Marketa Wills, M.D., CEO and medical director of the American Psychiatric Association

Medicare should wait on approving coverage for Wegovy, by Alissa S. Chen

Although by a thoughtful doctor, this article is heavy on feelings and short on empirical arguments. You may feel like it is not a good idea, and that can be your personal belief, but that does not warrant its being used as evidence against a treatment that has been clinically demonstrated to have benefits beyond weight loss. Research on older patients is scarce but where isnt that the case except for drugs intended to ameliorate dementia? How long do we wait before trying this apparently efficacious treatment?

Steven Struhl, Converge Analytic

***

Please do not minimize semaglutide by equating it as merely affecting appetite to counteract late night snacking. The SELECT trial demonstrated that in persons with BMI of 27 or higher and without diabetes who had prior heart attack, stroke or peripheral artery disease, taking semaglutide versus placebo was associated with 20% reduction in subsequent heart attack, stroke and cardiovascular death! (Disclosure: I co-chaired the Steering Committee for SELECT and have received compensation for consulting from Novo Nordisk and many other makers of obesity medications and devices.)

This landmark study is important knowledge for every physician, and especially those in obesity medicine. The SELECT trial studied 17,706 patients and more than 6,000 were age 65 or older. It used the most rigorous methodology and was executed with precision. The FDA gave Wegovy an indication for secondary prevention of cardiovascular disease after rigorous review.

Lets be serious about offering this medication to people who need it. It is not a lifestyle medication. Medicare made the right decision in providing reimbursement for secondary prevention of cardiovascular disease.

Donna Ryan, Pennington Biomedical Research Center

***

As a patient, Im disappointed we have experts encouraging Medicare NOT to pay for semaglutide and tirzepatide. I am 69 years old and I go to my PCPs office weekly to get my injection administered. The entire cost is $350 for semaglutide for four weeks, and $450 for the tirzepatide for four weeks. I have been doing this for 14 months, had no adverse side effects whatsoever and have lost 50+ pounds thus far. While this is doable for me, I realize many others are not as fortunate. I would like to see Medicare follow the lead of private insurers and start covering part or all of the cost.

Penny Ogden

***

Im 66 and started on prescription Zepbound in February of 2024. I have lost weight, blood pressure is down, not sure about cholesterol though. Not only does Medicare not pay for it but they also do not allow us to get the huge discount coupon from the manufacturer. Not really sure if Ill be able to afford this medication much longer, which is quite sad.

Tracey Black

***

As a 68-year-old female who has taken Ozempic for 17 months and had it ripped away with Medicare deciding not to cover it for those with pre-diabetes, I have to say I feel much worse now that the weight has come back, along with incessant hunger. In four months my A1C, blood pressure, and cholesterol went up. My life is again centered around what I can and should not eat and it is a constant battle that can be won short term, but not long term.

Ozempic helped my weight stay constant. I loved the once a week shot and then could forget about it. I drank lots of water and got plenty of exercise. Clothes felt good. Now it is depressing. Cant move as well, nothing fits and just cant get my weight to stop climbing no matter how much I exercise. Medicare should approve this treatment for older people. Let each doctor decide by patient if it should be used, not the government!

S R Bratton

Congress called for an ALS moonshot. The plan for it doesnt leave Earth, by Bernie Zipprich

This is an excerpt of my testimony to the National Academies of Sciences, Engineering, and Medicine on my plan to make ALS a livable disease in 10 years:

With veterans 60% more likely to develop ALS, it is imperative that we serve those whove served in the armed forces. Nonprofit organizations like Paralyzed Veterans of America (PVA) are uniquely staffed with national service officers who are ALS benefits experts. In partnership with the Veterans Administration, PVAs Medical Services team conducts site visits across the country, engaging with ALS specialists.

It was on such a visit that I met Dr. Richard Reimer, medical director of the ALS Clinic at the Palo Alto VA. Collaborating with the Lawrence Livermore National Lab, Dr. Reimer is using its world-class supercomputer, investigating drugs to repurpose for ALS.

Another study, facilitated by The National ALS Registry, assesses Military exposures and ALS in a large Veteran population. Data from the Department of Defense and VA will capture military factors such as branch of service, occupation, deployment, demographic, and de-identified health data.

According to a Project MinE study, 15% of people with Sporadic ALS have a genetic component while regional fine-mapping has identified an additional 690 new ALS-risk genes. This supports the opinion that ALS has multifactorial causes and that genetic testing should be routinely offered as a standard of care.

In conclusion, I would like to echo the sentiments of Retired Marine Corps infantry officer, Chris Mulholland, who has been battling ALS since November 2020. In a Military Times article titled, ALS is Killing Veterans, Chris wrote, If you know of a Veteran who has or had ALS, we need you in this fight. Too often ALS exists in the shadows, and those afflicted pass so quickly they cant speak for themselves. Be their voice!

Juliet Pierce, Paralyzed Veterans of America

Originally posted here:
First Opinion readers respond to psychiatry and social contracts, Medicare and weight loss meds, and more - STAT

Read More..

Summary

Things have been working well for the 90 Day Fianc star David Toborowsky, and besides taking steps towards welcoming a child, he has been focusing on his health, with his face looking much thinner. A great number of pictures are enough evidence that David's looks have improved since his first appearance on 90 Day Fianc. He once shared a photo on his Instagram with Annie Suwan Toborowsky in 2018, with the 90 Day Fianc star looking slim and toned. At one point, David gained some weight, but he has dropped a few pounds over the last few years.

His relationship with Annie captured many people's attention due to their huge age difference. Annie and David's growth as a couple has been pretty evident throughout their journey. However, that's not the only thing. David's transformation has gone down in history as one of the best body transformations ever. David started going through the weight-loss journey in 2020, looking forward to taking control of his health. Although he has managed to get it under control, David's eyebrow transformation has gone too far as he tries to tweak his image.

Reality TV is more popular than ever. With so many to choose from, here are some of the best reality TV shows to stream or watch right now.

Like many other people who've had body makeovers, David would likely admit that the journey can be tough and cruel. The 90 Day Fianc star has been open about his healthy lifestyle. In addition to eating the right foods, David is taking vitamins and walking. Those things are his not-so-secret weapons for a lean and well-toned body. See David in his Instagram post with Annie Suwan Toborowsky, as shown above.

David recently debuted a new look, showing his neatly micro-bladed eyebrows as he shared an update on their pregnancy journey. His face looked lean and fresh. The eyebrows are also quite stylish - however, they look a bit too thin for David's round face. He seems to have gone quite far this time. Some fans didn't love this look, with one rudely telling David he looked more feminine than ever.

"With all due respect, the eyebrows look very feminine."

David's weight-loss journey has been so remarkable. He initially gained weight after returning to the United States in 2020 from Thailand. His progress was visible during David & Annie: After 90 The Days season 2. At that time, the Louisville native had lost over 70 pounds.

Annie loves to cook. She has been making some fresh and nutrient-dense meals that have helped keep David's weight in check. Therefore, David will most likely continue to lose weight and achieve his expected goal. However, the 90 Day Fianc star doesn't need further face procedures since he still looks youthful.

David has been on a self-improvement journey. It isn't only his toned face that is visible, but also his pearly white teeth and his smooth and youthful-looking skin, as shown in his recent Instagram update (via David Toborowsky). Obviously, David wanted to look as young as his wife, given the age gap between the two.

There is nothing wrong with that. Nevertheless, with the constant cosmetic procedures that he is undertaking, David might get a little bit obsessed. Things could get out of hand. While he may be getting a lttile too thin and vain these days, he seems happy. The 90 Day Fianc reality star's body transformation and face makeover's improved his smile and boosted his confidence.

90 Day Fianc: Happily Ever After? season 8 airs Sundays at 8 p.m. EDT on TLC

Sources: Annie Suwan Toborowsk/Instagram, David Toborowsky/Instagram

90 Day Fianc: Happily Ever After? is one of the many spinoff shows to TLCs 90 Day Fianc. Happily Ever After? provides viewers with a follow-up to some of the most popular couples from the original show. The companion series reveals if lovers ended up staying in their marriage and explores any major life events or issues they may be facing.

/Instagram

Follow this link:
90 Day Fianc: Is David Toborowsky Getting Too Thin After Weight Loss & Eyebrow Makeover? - Screen Rant

Read More..

Contact Us Today

Page 13«..10..12131415..2030..»

Home » Page 13